Preview

Вестник трансплантологии и искусственных органов

Расширенный поиск

ГЕМОДИАФИЛЬТРАЦИЯ. ИСТОРИЯ, РАЗВИТИЕ И СОВРЕМЕННЫЕ СТАНДАРТЫ

https://doi.org/10.15825/1995-1191-2014-1-54-64

Полный текст:

Аннотация

В настоящее время гемодиафильтрация является наиболее эффективной методикой диализа благодаря комбинации диффузионного и конвективного транспорта через мембрану гемодиафильтра. В первой час- ти обзора рассмотрены исторические, технические аспекты и международные стандарты для онлайн ге- модиафильтрации. 

Об авторах

Я. Л. Поз
Отделение гемодиализа ФГБУ «Федеральный научный центр трансплантологии и искусственных органов им. академика В.И. Шумакова» Минздрава РФ, Москва, Российская Федерация

 



А. Г. Строков
Отделение гемодиализа ФГБУ «Федеральный научный центр трансплантологии и искусственных органов им. академика В.И. Шумакова» Минздрава РФ, Москва, Российская Федерация


Ю. В. Копылова
Отделение гемодиализа ФГБУ «Федеральный научный центр трансплантологии и искусственных органов им. академика В.И. Шумакова» Минздрава РФ, Москва, Российская Федерация


Список литературы

1. СПИСОК ЛИТЕРАТУРЫ / REFERENCES

2. Foley R.N., Parfrey P.S., Harnett J.D., Kent G.M, Mar- tin C.J., Murray D.C., Barre P.E. Clinical and echocar- diographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995; 47: 186–192.

3. Blacher J., Guerin A.P., Pannier B., Marchais S.J,, Sa- far M.E., London G.M. Impact of aortic stiffness on sur- vival in end-stage renal disease. Circulation. 1999; 99: 2434–2439.

4. Kato A., Takita T., Maruyama Y. Impact of carotid athe- rosclerosis on long-term mortality in chronic hemodialy- sis patients. Kidney Int. 2003; 64: 1472–1479.

5. Himmelfarb J., Stenvinkel P., Ikizler T.A., Hakim R.M. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int.

6. ; 62: 1524–1538.

7. Vanholder R., Glorieux G., Lameire N. Uraemic toxins

8. and cardiovascular disease. Nephrol. Dial. Transplant.

9. ; 18: 463–466.

10. Cheung A.K., Sarnak M.J., Yan G., Dwyer J.T., Hey-

11. ka R.J., Rocco M.V., Teehan B.P., Levey A.S. Atheroscle- rotic cardiovascular disease risks in chronic hemodialy- sis patients. Kidney Int. 2000; 58: 353–362.

12. Block G.A., Hulbert-Shearon T.E., Levin N.W., Port F.K. Association of serum phosphorus and calcium × phos- phate product with mortality risk in chronic hemodialy- sis patients: a national study. Am. J. Kidney Dis. 1998; 31: 607–617.

13. Young E.W., Akiba T., Albert J.M., McCarthy J.T., Kerr P.G., Mendelssohn D.C., Jadoul M. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 2004; 44 (Suppl 3): 34–38.

14. Henderson L.W., Besarab A., Michaels A., Bluemle L.W. Jr. Blood purification by UF and fluid replacement (dia- filtration). Trans. Am. Soc. Artif. Intern. Organs. 1967; 17: 216–221.

15. Henderson L.W., Colton C.K., Ford C. Kinetics of HDF. II. Clinical characterization of a new blood cleansing modality. J. Lab. Clin. Med. 1975; 85: 372–375.

16. Leber H.W., Wizemann V., Goubeaud G., Rawer P., Schütterle G. Hemodiafiltration: a new alternative to hemofiltration and conventional hemodialysis. Artif. Or- gans. 1978; 2: 150–153.

17. Hoenich N., Ronco C. Dialyzer evaluation. Winchester J., Koch K., Jacobs C., Kjiellestrand C. (eds): Replacement of Renal Function by Dialysis. 4th edn. Dordrecht, Kluwer Academic Publishers, 1996: 256–270.

18. Pacitti A., Casino F.G., Pedrini L., Santoro A., Atti M. Prescription and surveillance of the acetate-free biofiltra- tion sessions: the bicarbonate cycle. Int. J. Artif. Organs. 1995; 18: 722–725.

19. Ledebo I., Ronco C. The best dialysis therapy? Results from an international survey among nephrology profes- sionals. NDT Plus. 2008; 6: 403–408.

20. Bhimani J.P., Ouseph R., Ward R.A. Reducing dialysate boundary layer resistance by increasing dialysate flow rate increases diffusive mass transfer of phosphorous but not urea nor beta-2-microglobulin in dialyzers with fiber undulations (abstract). J. Am. Soc. Nephrol. 2008; 19: 460A.

21. Eknoyan G., Beck G.J., Cheung A.K., Daugirdas J.T., Greene T., Kusek J.W., Allon M., Bailey J., Delmez J.A., Depner T.A., Dwyer J.T., Levey A.S., Levin N.W., Milford E., Ornt D.B., Rocco M.V., Schulman G., Schwab S.J., Teehan B.P., Toto R. Hemodialysis (HEMO) Study Group. Effect of dose and membrane flux in main- tenance hemodialysis. N. Engl. J. Med. 2002; 347: 2010– 2019.

22. Ledebo I., Blankestijn P.J. Haemodiafiltration – optimal efficiency and safety. NDT Plus. 2010; 3: 8–16.

23. Ledebo I. Principles and practice of hemofiltration and hemodiafiltration. Artif. Organs. 1998; 22: 20–25.

24. Jaffrin M. Convective mass transfer in hemodialysis. Ar- tif. Organs. 1995; 19: 1162–1171.

25. Penne E.L., Van Der Weerd N.C., Bots M.L., van den Dor- pel M.A., Grooteman M.P., Lévesque R., Nubé M.J., Ter Wee P.M., Blankestijn P.J. CONTRAST investigators. Patient- and treatment-related determinants of convecti- ve volume in post-dilution haemodiafiltration in clinical practice. Nephrol. Dial. Transplant. 2009; 24: 3493– 3499.

26. Joyeux V., Sijpkens Y., Haddj-Elmrabet A. Optimized convective transport with automated pressure control in on-line postdilution hemodiafiltration. Int. J. Artif. Or- gans. 2008; 31: 928–936.

27. Colussi G., Frattini G. Quantitative analysis of convec- tive dose in hemofiltration and hemodiafiltration: ‘pre- dilution’ versus ‘postdilution’ reinfusion. Hemodial. Int. 2007; 11: 76–85.

28. Fischbach M., Dheu C., Menouer S., Terzic J. In-center daily on-line hemodiafiltration: 4-year experience in children. Clin. Nephrol. 2008; 69: 279–294.

29. Pedrini L.A., De Christofaro V. On-line mixed hemo- diafiltration with feedback for ultrafiltration control: ef- fect on middle molecule removal. Kidney Int. 2003; 64: 1505–1513.

30. Pedrini L., Cozzi G., Faranna P., Mercieri A., Rug- giero P., Zerbi S., Feliciani A., Riva A. Transmembrane pressure modulation in high-volume mixed hemodiafil- tration to optimize efficiency and minimize protein loss. Kidney Int. 2006; 69: 573–579.

31. www.highvolumehdf.com

32. Pedrini L.A., De Cristofaro V., Pagliari B., Sama F.

33. Mixed predilution and postdilution online hemodiafiltra- tion compared with the traditional infusion modes. Kid- ney Int. 2000; 58: 2155–2165.

34. Tattersall J.E., Ward R.A. Online haemodiafiltration: de- finition, dose quantification and safety revisited. Neph- rol. Dial. Transplant. 2013; 22: 542–550.

35. Pedrini L., Feliciani A., Zerbi S., Cozzi G., Ruggiero P. Optimization of mid-dilution haemodiafiltration: technique and performance. Nephrol. Dial. Transplant. 2009; 24: 2816–2824.

36. Krieter D.H., Falkenhain S., Chalabi L., Collins G., Lemke H.D., Canaud B. Clinical cross-over comparison of mid-dilution hemodiafiltration using a novel dialyzer concept and post-dilution hemodiafiltration. Kidney Int. 2005; 67: 349–356.

37. Usuda M., Shinzato T., Sezaki R., Kawanishi A., Mae- da K., Kawaguchi S., Shibata M., Toyoda T., Asaku- ra Y., Ohbayashi S. New simultaneous HF and HD with no infusion fluid. Trans. Am. Soc. Artif. Organs. 1982; 28: 24–27.

38. Shinzato T., Fujisawa K., Nakai S., Miwa M., Kobayaka- wa H., Takai I., Morita H., Maeda K. Newly developed economical and efficient push/pull hemodiafiltration. Maeda K., Shinzato T. (eds): Effective Hemodiafiltra- tion: New Methods / Contrib. Nephrol. Basel, Karger, 1994; 108: 79–86.

39. Ronco C., Canaud B., Aljama P. (eds): Hemodiafiltra- tion. Contrib. Nephrol. Basel, Karger, 2007; 158: 169– 176.

40. 34. von Albertini B., Miller J.H., Gardner P.W., Shinaber- ger J.H. High-flux hemodiafiltration: under six hours/ week treatment. Trans. Am. Soc. Artif. Intern. Organs. 1984; 30: 227–231.

41. Yamashita A.C. New dialysis membrane for removal of middle molecule uremic toxins. Am. J. Kidney Dis. 2001; 38 (Suppl 1): 217–219.

42. Stenvinkel P., Alvestrand A. Inflammation in end-stage renal disease: sources, consequences and therapy. Semin. Dial. 2002; 15: 329–337.

43. Grassmann A., Gioberge S., Moeller S., Brown G. End- stage renal disease: global demographics in 2005 and observed trends. Artif. Organs. 2006; 30: 895–897.

44. Canaud B., N’Guyen Q.V., Lagarde C., Stec F., Polas- chegg H.D., Mion C. Clinical evaluation of a multi- purpose dialysis system adequate for hemodialysis or for postdilution hemofiltration/ hemodiafiltration with on-line preparation of substitution fluid from dialysate. Contr. Nephrol. 1985; 46: 184–186.

45. Henderson L.W., Sanfelippo M.L., Beans E. On-line preparation of sterile pyrogen-free electrolyte solution. Trans. ASAIO. 1978; 24: 465–467.

46. Shinzato T., Sezaki R., Usuda M., Maeda K., Ohbayas- hi S., Toyota T. Infusion-free hemodiafiltration: simulta- neous hemofiltration and dialysis with no need for infu- sion fluid. Artif. Organs. 1982; 6: 453–456.

47. Canaud B., Flavier J.L., Argilés A. Hemodiafiltration with on-line production of substitution fluid: long-term safety and quantitative assessment of efficacy. Contrib. Nephrol. 1994; 108: 12–22.

48. Canaud B., Nguyen Q.V., Argilés A., Polito C., Polas- cheoo H.D., Mion C. Hemodiafiltration using dialysate as substitution fluid. Artif. Organs. 1987; 11: 188–190.

49. International Electrotechnical Commission. IEC 60601, Medical electrical equipment – Part 2-16, Particular re- quirements for basic safety and essential performance of haemodialysis, haemodiafiltration and haemofiltration equipment. 3rd edn / Geneva, Switzerland, 2008.

50. International Organization for Standardization. Quality of dialysis fluid for haemodialysis and related therapies (ISO 11663:2009) / Geneva: International Organization for Standardization, 2009.

51. Tsuchida K., Takemoto Y., Yamagami S., Edney H., Niwa M., Tsuchiya M., Kishimoto T., Shaldon S. Detec- tion of peptidoglycan and endotoxin in dialysate, using silkworm larvae plasma and limulus amebocyte lysate methods. Nephron. 1997; 75: 438–443.

52. Schindler R., Beck W., Deppisch R., Aussieker M., Wil- de A., Göhl H., Frei U. Short bacterial DNA fragments:

53. detection in dialysate and induction of cytokines. J. Am.

54. Soc. Nephrol. 2004; 15: 3207–3214.

55. Ward R.A. Worldwide water standards for hemodialysis.

56. Hemodial. Int. 2007; 11: S18–S25.

57. Schindler R., Ertl T., Beck W., Lepenies J., Boenisch O., Op-

58. permann M., Kaspar E., Frei U. Reduced cytokine induc- tion and removal of complement products with synthetic hemodialysis membranes. Blood Purif. 2006; 24: 203–211.

59. Pereira B.J., Snodgrass B.R., Hogan P., King A.J. Dif- fusive and convective transfer of cytokine-inducing bac- terial products across hemodialysis membranes. Kidney Int. 1995; 47: 603–610.

60. Panichi V., De Pietro S., Andreini B., Migliori M., Tes- sore V., Taccola D., Rindi P., Palla R., Tetta C. Cytokine production in haemodiafiltration: a multicentre study. Nephrol. Dial. Transplant. 1998; 13: 1737–1744.

61. Ledebo I. Ultrapure dialysis fluid-direct and indirect be- nefits in dialysis therapy. Blood Purif. 2004; 22 (Suppl 2): 20–25.

62. Bommer J., Becker K.P., Urbaschek R. Potential transfer of endotoxin across high-flux polysulfone membranes. J. Am. Soc. Nephrol. 1996; 7: 883–888.

63. Masakane I. Review: clinical usefulness of ultrapure dialysate-recent evidence and perspectives. Ther. Apher. Dial. 2006; 10: 348–354.

64. Ledebo I. Ultrapure dialysis fluid – how pure is it and do we need it? Nephrol. Dial. Transplant. 2007; 22: 20–23.

65. European Best Practice Guidelines for Haemodialysis (Part 1), SECTION IV. Dialysis fluid purity. Nephrol.

66. Dial. Transplant. 2002; 17 (Suppl 7): 45–62.

67. Kawanishi H., Akiba T., Masakane I., Tomo T., Mineshi- ma M., Kawasaki T., Hirakata H., Akizawa T. Standards on microbiological management of fluids for hemodialy- sis and related therapies by the Japanese society for dia- lysis therapy 2008. Ther. Apher. Dial. 2009; 13: 161–166.

68. Penne E.L., Visser L., van den Dorpel A., van der Weerd N.C., Mazairac A.H., van Jaarsveld B.C., Koop- man M.G., Vos P., Feith G.W., Kremer Hovinga T.K., van Hamersvelt H.W., Wauters I.M., Bots M.L., Nubé M.J., Ter Wee P.M., Blankestijn P.J., Grooteman M.P. Microbiolo- gical quality and quality control of purified water and ult- rapure dialysis fluids for online hemodiafiltration in routi-

69. ne clinical practice. Kidney Int. 2009; 76: 665–672.

70. Guth H.-J., Gruska S., Kraatz G. On-line production of ultrapure substitution fluid reduces TNF-alpha- and IL-6 release in patients on hemodiafiltration therapy. Int. J.

71. Artif. Organs. 2003; 26: 181–187.


Для цитирования:


Поз Я.Л., Строков А.Г., Копылова Ю.В. ГЕМОДИАФИЛЬТРАЦИЯ. ИСТОРИЯ, РАЗВИТИЕ И СОВРЕМЕННЫЕ СТАНДАРТЫ. Вестник трансплантологии и искусственных органов. 2014;16(1):54-64. https://doi.org/10.15825/1995-1191-2014-1-54-64

For citation:


Poz Y.L., Strokov A.G., Kopylova Y.V. HEMODIAFILTRATION. HISTORY, EVOLUTION, CONTEMPORARY STANDARDS. Russian Journal of Transplantology and Artificial Organs. 2014;16(1):54-64. (In Russ.) https://doi.org/10.15825/1995-1191-2014-1-54-64

Просмотров: 656


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-1191 (Print)
ISSN 2412-6160 (Online)